MediWound (MDWD) Stock Price, News & Analysis

Company Overview

MediWound Ltd. (NASDAQ: MDWD) is a commercial-stage biotechnology company focused on developing and marketing innovative enzymatic therapies for complex wounds. The company’s products are designed to support the removal of damaged tissue and improve wound management, with an emphasis on severe burns and hard-to-heal chronic wounds.

MediWound’s lead product, NexoBrid, is a bromelain-based topical biological product used for the enzymatic removal of eschar, or dead tissue, from deep partial-thickness and full-thickness thermal burns. NexoBrid has received regulatory approvals in multiple markets, including the United States, the European Union and Israel. In the United States, the product is commercialized through a partnership with Vericel Corporation.

The company is also developing EscharEx, an investigational enzymatic treatment intended to remove nonviable tissue from chronic wounds, including venous leg ulcers. MediWound was founded in 2001 and is headquartered in Yavne, Israel. Its operations and commercial activities serve healthcare markets in North America, Europe, Israel and other international regions.

Key Stats

• Today's Range: $12.46 to $13.52
• 50-Day Range: $11.85 to $14.25
• 52-Week Range: $11.80 to $19.70
• Volume: 64,658 shs
• Average Volume: 97,535 shs
• Market Capitalization: $173.51 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $33.00
• Consensus Rating: Moderate Buy

MediWound Stock Analysis - MarketRank™

MediWound scored higher than 51% of companies evaluated by MarketBeat, and ranked 522nd out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

MediWound has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

MediWound has a consensus price target of $33.00, representing about 145.7% upside from its current price of $13.43.

Amount of Analyst Coverage

MediWound has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for MediWound are expected to grow in the coming year, from ($2.37) to ($2.30) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MediWound is -7.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MediWound is -7.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MediWound has a P/B Ratio of 3.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.16% of the float of MediWound has been sold short.

Short Interest Ratio / Days to Cover

MediWound has a short interest ratio ("days to cover") of 14.73, which indicates bearish sentiment.

Change versus previous month

Short interest in MediWound has recently increased by 2.32%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MediWound does not currently pay a dividend.

Dividend Growth

MediWound does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.63

News Sentiment

MediWound has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for MediWound this week, compared to 2 articles on an average week.

Search Interest

3 people have searched for MDWD on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, MediWound insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $75,382.00 in company stock.

Percentage Held by Insiders

9.20% of the stock of MediWound is held by insiders.

Percentage Held by Institutions

46.83% of the stock of MediWound is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 11/12/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MDWD
• CIK: 1593984
• Web: www.mediwound.com
• Phone: 972779714100
• Fax: 972-77-971-4111
• Employees: 121
• Year Founded: 2001

Price Target and Rating

• Average Price Target for MediWound: $33.00
• High Price Target: $36.00
• Low Price Target: $30.00
• Potential Upside/Downside: +147.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.80)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$23.88 million
• Net Margins: -170.10%
• Pretax Margin: -168.90%
• Return on Equity: -47.24%
• Return on Assets: -24.27%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.32
• Quick Ratio: 2.09

Sales & Book Value

• Annual Sales: $11.86 million
• Price / Sales: 14.63
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.40 per share
• Price / Book: 3.92

Miscellaneous

• Outstanding Shares: 13,010,000
• Free Float: 11,813,000
• Market Cap: $173.55 million
• Optionable: Optionable
• Beta: 0.07